Post-marketing safety profile of lumacaftor/ivacaftor in cystic fibrosis treatment: a pharmacovigilance analysis based on FAERS.

Reports submitted by consumers were more likely to report depressive events compared to those submitted by healthcare professionals, though the result did not reach statistical significance (OR = 2.062, 95% CI: 0.972–4.372, p = 0.059).

also in 111,027 other papers

In terms of temporal distribution, the number of LUM/IVA-related reports remained high from 2016 to 2019 (with over 1,300 reports per year), but showed a decreasing trend starting since 2019 ( Figure 2A ).

also in 47,180 other papers